Monday, February 19, 2018
2015

Yearly STL Archives: 2015

Update on Drugs and Drug News: November-December 2015

Update on Polidocanol 1% injectable foam (Varithena®), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Adalimumab SC injection (Humira®), Hyaluronic acid filler (Juvederm® Ultra XC), Nivolumab + ipilimumab (Opdivo® + Yervoy®), Ingenol mebutate gel (Picato®)

Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis

Onychomycosis is a stubborn fungal infection of the nails that can be difficult to manage. Clinical trial data of Tavaborole is considered, as it allows for effective nail penetration compared to ciclopirox and amorolfine lacquers.

Sugar Sag: Glycation and the Role of Diet in Aging Skin

Increased accumulation of AGEs in human tissue has been associated with serious medical concerns including end stage renal disease, chronic obstructive pulmonary disease, and, recently, skin aging. In this review, we summarize the evidence supporting the role of glycation in skin aging.

Update on Drugs and Drug News: September-October 2015

Update on Nivolumab IV infusion (Opdivo®), Pembrolizumab IV infusion (Keytruda®), Sonidegib phosphate capsules (Odomzo®), Azelaic acid 15% foam (Finacea® Foam), Adapalene 0.3% + benzoyl peroxide 2.5% gel (Epiduo® Forte), Deoxycholic acid injection (Belkyra™), Hyaluronic acid gel injectable dermal filler (Restylane® Lyft with Lidocaine), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® (+)

New Antibiotics in the Management of Acute Bacterial Skin and Skin...

This article reviews the mechanism of action, efficacy, bacterial coverage, and potential side effects for dalbavancin and oritavancin, both semisynthetic lipoglycopeptide antibiotics, and tedizolid, an oxazolidinone.

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis

Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines. A review of clinical trial data treating psoriasis, considering adverse effects, efficacy and tolerance.

Update on Drugs and Drug News: July-August 2015

Update on Deoxycholic acid injection (Kybella™), Ivermectin 1% cream (Rosiver®), Adalimumab SC injection (Humira®), Apremilast tablets (Otezla®), and Dermal filler with calcium hydroxylapatite (CaHA) (Radiesse®)

Ivermectin 1% Cream for Rosacea

The etiology of papulopustular rosacea (PPR) is not well understood yet appears to involve both the innate and adaptive immune response in addition to possible infestation with Demodex mites. This article reviews data on Ivermectin cream 1%, a new topical treatment for PPR.

Hidradenitis Suppurativa: A Review with a Focus on Treatment Data

Hidradenitis suppurativa (HS) is a chronic disease of the follicular unit that often leads to marked impairment of quality of life. This article reviews various treatment modalities for HS including laser, surgery, retinoids, immunosuppression, biologics, and antibiotics.

Update on Drugs and Drug News: May-June 2015

Update on Varicose vein n-butyl-2-cyanoacrylate adhesive polymer (VenaSeal™ Closure System), Dermal filler + calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse®), Dalbavancin for IV injection (Xydalba™), Pembrolizumab for IV infusion (Keytruda®)

Current Management of Scalp Psoriasis

The scalp is involved in up to 80% of individuals with psoriasis. Topical treatment with corticosteroids with or without vitamin D3 analogues is the mainstay of treatment, but other therapies such as light treatment and systemic drugs including biologics are discussed.

Regulating Off-label Promotion of Medications: Has the Pendulum Swung Too Far?

Prescribing medications off-label is commonplace in dermatology. This article discusses the recent FDA policy chances, the debate on free speech, the benefits and risks of off label drug use and promotion, and how it relates to patient care.

Update on Drugs and Drug News: March-April 2015

Update on Human papillomavirus 9-valent vaccine, recombinant (Gardasil®9), Ivermectin 1% cream (Soolantra®), Naftifine HCl 2% gel & cream (Naftin®), Nivolumab IV infusion (Opdivo®), Polymethylmethacrylate collagen dermal filler for acne scars (Bellafill®), Secukinumab SC injection (Consentyx™).

Skin Treatments Introduced in 2014

An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.

Male Aesthetics

Men are a fast growing segment of the aesthetic industry. This article discusses important gender differences in facial anatomy and behavior that are relevant, as well as the requirement for different injection techniques when using dermal fillers and Botulinum toxins.

Interleukin-23 in the Pathogenesis and Treatment of Psoriasis

In the past three decades, major advances have been made in understanding the pathogenesis of psoriasis. This review focuses on the role of IL-23 in psoriasis pathogenesis and the current therapies targeting IL-23 that are being studied in clinical trials.

Update on Drugs and Drug News: January-February 2015

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

Sinecatechins 10% Ointment: A Green Tea Extract for the Treatment of...

External genital warts resulting from HPV are a common sexually transmitted infection. This article reviews data on Sinecatechins 10% ointment (a Green Tea extract), a new botanically based patient-administered therapy for external genital warts.

Interleukin-17 (IL-17) Inhibitors in the Treatment of Plaque Psoriasis: A Review

Interleukin-17 (IL-17) is believed to be a potent driver of plaque psoriasis. This article reviews efficacy and safety results from Phase 2 and 3 trials with monoclonal antibodies targeting IL-17RA (brodalumab), and IL-17A (ixekizumab and secukinumab) for the treatment of plaque psoriasis.

LATEST: VOL 23-1, JAN 2018

New Treatments for Hereditary Angioedema

Recent advances in the treatment of hereditary angioedema, particularly in the last decade has been promising. This paper reviews the mechanisms, efficacy, and adverse reactions associated with these new treatment medications. 
Dietary Change as a Treatment Strategy for Skin Disease

Skin and Diet: An Update on the Role of Dietary Change as a Treatment...

An increasing body of research indicates that dietary change may serve as a component of therapy for certain skin conditions. This includes conditions such as acne, atopic dermatitis, aging skin, psoriasis, and rosacea. This article takes a high level overview of the role that diet may play in these conditions.

Update on Drugs and Drug News: January-February 2018

Update on drugs includes Onabotulinum-toxinA for injection (Botox® Cosmetic), Hyaluronic acid dermal filler (Restylane® Silk), Ustekinumab for SC injection (Stelara®), Golimumab for IV infusion (RSimponi Aria®), Herpes zoster vaccine (non-live recombinant, AS01B adjuvanted) suspension for IM injection (Shingrix), Brentuximab vedotin for IV infusion (Adcetris®)

POPULAR